Vanguard Group
ADCT icon

Vanguard Group’s ADC Therapeutics ADCT Stock Holding History

Vanguard Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.99M Buy
1,129,587
+535,633
+90% +$2.17M ﹤0.01% 3338
2025
Q3 		$2.38M Buy
593,954
+33,431
+6% +$105K ﹤0.01% 3526
2025
Q2 		$1.5M Sell
560,523
-91,484
-14% -$192K ﹤0.01% 3628
2025
Q1 		$919K Buy
652,007
+7,389
+1% +$12.6K ﹤0.01% 3738
2024
Q4 		$1.28M Buy
644,618
+105,259
+20% +$275K ﹤0.01% 3687
2024
Q3 		$1.7M Buy
539,359
+135,130
+33% +$426K ﹤0.01% 3605
2024
Q2 		$1.28M Buy
+404,229
New +$1.61M ﹤0.01% 3712

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return